Clinical ResearchCYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome
Under an Elsevier user license
open archive
Key Words
acute coronary syndrome
bleeding
genotyping
platelet testing
prasugrel
Abbreviations and Acronyms
ACS
acute coronary syndrome
ADP
adenosine diphosphate
ADP-Ag
adenosine diphosphate–induced platelet aggregation
BARC
Bleeding Academic Research Consortium
CI
confidence interval
CYP
cytochrome P450
HTPR
high on-treatment platelet reactivity
LTA
light transmittance aggregometry
OR
odds ratio
MFI
median fluorescence intensity
PCI
percutaneous coronary interventions
PCR
polymerase chain reaction
PGE1
prostaglandin E1
PRI
platelet reactivity index
TIMI
Thrombolysis In Myocardial Infarction
VASP
vasodilator-stimulated phosphoprotein
Cited by (0)
Dr. Cuisset has received consultant fees from Daiichi-Sankyo and Eli Lilly, and lecture fees from AstraZeneca, Abbott Vascular, Biotronik, Boston Scientific, Cordis, Daiichi-Sankyo, Edwards, Eli Lilly, Sanofi-Aventis, and Servier. Dr. Alessi has been a regional board member of Eli Lilly and received research funding from Sanofi-Aventis. The other authors have stated that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.